Skip to content
10-Q

Quarterly Report

Alamar Biosciences, Inc. ALMR

0001193125-26-213424

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 69.31M sh
Shares Diluted Q1 2026 · Mar 31, 2026 12.26M sh
Shares Diluted Q1 2026 · Mar 31, 2025 11.26M sh
Capex Q1 2026 · Mar 31, 2026 $600K
Capex Q1 2026 · Mar 31, 2025 $554K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$20.35M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.07M
Short Term Investments Q1 2026 · Mar 31, 2026 $0
Short Term Investments Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $64.59M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $30M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$178.07M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$158.95M
Current Liabilities Q1 2026 · Mar 31, 2026 $24.05M
Current Liabilities Q1 2026 · Dec 31, 2025 $23.73M
Total Liabilities Q1 2026 · Mar 31, 2026 $129.53M
Total Liabilities Q1 2026 · Dec 31, 2025 $63.95M
Current Assets Q1 2026 · Mar 31, 2026 $141.47M
Current Assets Q1 2026 · Dec 31, 2025 $94.71M
Total Assets Q1 2026 · Mar 31, 2026 $186.45M
Total Assets Q1 2026 · Dec 31, 2025 $139.99M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.74
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.68
Eps Basic Q1 2026 · Mar 31, 2026 −$1.74
Eps Basic Q1 2026 · Mar 31, 2025 −$0.68
Sga Expense Q1 2026 · Mar 31, 2026 $13.79M
Sga Expense Q1 2026 · Mar 31, 2025 $6.64M
Rd Expense Q1 2026 · Mar 31, 2026 $13.02M
Rd Expense Q1 2026 · Mar 31, 2025 $8.3M
Net Income Q1 2026 · Mar 31, 2026 −$21.33M
Net Income Q1 2026 · Mar 31, 2025 −$7.66M
Operating Income Q1 2026 · Mar 31, 2026 −$12.35M
Operating Income Q1 2026 · Mar 31, 2025 −$8.55M
Gross Profit Q1 2026 · Mar 31, 2026 $14.46M
Gross Profit Q1 2026 · Mar 31, 2025 $6.39M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $11.58M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $6.7M
Revenue Q1 2026 · Mar 31, 2026 $26.04M
Revenue Q1 2026 · Mar 31, 2025 $13.09M